PODD Key Stats
- Nasdaq stocks posting largest percentage increases May 20
- INSULET CORP Files SEC form 8-K, Unregistered Sale of Equity Securities May 20
- Medical Products Companies, Particularly Those Aimed at Surgical Procedures, Gen... May 17
- INSULET CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Hol... May 17
- Insulet Corporation to Present at Upcoming Investor Conferences Marketwired May 15
- UPDATE: Barrington Downgrades Insulet to Market Perform Following on Valuation Benzinga May 9
- INSULET CORP Files SEC form 10-Q, Quarterly Report May 8
- Northland Securities Downgrades Insulet Corporation (PODD) to Market Perform Street Insider May 8
- Insulet downgraded by Northland Capital May 8
- Insulet Beats Up on Analysts Yet Again Fool May 7
PODD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Insulet Corporation is up 65.90% over the last year vs S&P 500 Total Return up 31.95%, DexCom up 103.1%, and Conceptus up 84.35%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for PODD
Pro Report PDF for PODD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PODD Pro Report PDF
Pro Strategies Featuring PODD
Did Insulet Corporation make it into our Pro Portfolio Strategies?
Insulet Corporation is an innovative medical device company based in Bedford, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. Specifically, through its revolutionary OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy. Insulet was founded by John L. Brooks III and John T. Garibotto.